US Stock MarketDetailed Quotes
CUE Cue Biopharma
- 0.960
- -0.085-8.13%
Trading Dec 13 13:53 ET
60.82MMarket Cap-1.05P/E (TTM)
1.030High0.940Low357.90KVolume1.030Open1.045Pre Close351.33KTurnover0.57%Turnover RatioLossP/E (Static)63.35MShares3.20052wk High2.40P/B60.34MFloat Cap0.45052wk Low--Dividend TTM62.86MShs Float31.690Historical High--Div YieldTTM8.61%Amplitude0.450Historical Low0.981Avg Price1Lot Size
About Cue Biopharma Company
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.
Company Profile
SymbolCUE
Company NameCue Biopharma
Listing DateJan 2, 2018
Issue Price7.50
Founded2014
CEOMr. Daniel R. Passeri
MarketNASDAQ
Employees53
Fiscal Year Ends12-31
Address40 Guest Street
CityBoston
ProvinceMassachusetts
CountryUnited States of America
Zip Code02135
Phone1-617-949-2680
Websitehttp://www.cuebiopharma.com
Company Executives
- Name
- Position
- Salary
- Daniel R. Passeri
- Chief Executive Officer and Director
- 3.02M
- Kerri-Ann Millar
- Chief Financial Officer and Principal Accounting Officer
- 1.16M
- Matteo Levisetti
- Chief Medical Officer
- --
- Anish Suri
- President and Chief Scientific Officer
- 1.24M
- Colin G. Sandercock
- Senior Vice President, General Counsel and Secretary
- --
- Dr. Frank Morich, M.D.,PhD
- Chairman of the Board
- 106.27K
- Pamela D. Garzone
- Director
- 141.83K
- Patrick Verheyen
- Director
- 135.31K
- Dr. Peter A. Kiener, D.Phil.
- Independent Director
- 144.18K
- Frederick W. Driscoll
- Independent Director
- 76.31K
Heat List
US
Overall
Symbol
Price
% Chg
No Data